Speaker Name: Dr. Richard Pratley, Medical Director, AdventHealth Diabetes Institute, Florida, United States.

Explore this expert session to:

• Understand how T2DM heterogeneity, disease stage, and phenotype-based risk may support more individualized treatment selection.
• Recognize the importance of glucose variability beyond HbA1c, including links to adverse CV outcomes and the need for postprandial control.
• Evaluate the role of sitagliptin and other DPP-4 inhibitors for HbA1c reduction, low hypoglycemia risk, weight neutrality, and postprandial glucose control.
• Interpret major trial findings on CV safety, heart failure risk, and use in high-risk populations.
• Apply case-based treatment principles for frailty, sarcopenia, cognitive decline, polypharmacy, CKD, and multimorbidity when selecting glucose-lowering therapy.